Oramed Pharmaceuticals Inc.
Clinical-stage company developing oral drug delivery for injectable medications.
ORMP | TA
Overview
Corporate Details
- ISIN(s):
- US68403P2039
- LEI:
- Country:
- Israel
- Address:
- 20 Mamilla Avenue, 9414904 Jerusalem
- Website:
- https://www.oramed.com
- Sector:
- Manufacturing
Description
Oramed Pharmaceuticals Inc. is a clinical-stage company focused on developing oral drug delivery systems for medications that are typically administered via injection. The company's core technology is its proprietary Protein Oral Delivery (POD™) platform, which is designed to protect therapeutic proteins from enzymatic degradation in the gastrointestinal tract and enhance their absorption into the bloodstream. Oramed's lead product candidate is an oral insulin capsule (ORMD-0801) for the treatment of diabetes. The company's pipeline also includes an oral GLP-1 analog capsule (ORMD-0901) for type 2 diabetes. Oramed aims to improve patient compliance, comfort, and therapeutic outcomes by converting injectable treatments into oral formulations.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2020-02-27 00:56 |
PRELIMINARY PROSPECTUS SUPPLEMENT
|
English | 279.2 KB | ||
| 2020-02-27 00:56 |
PRELIMINARY PROSPECTUS SUPPLEMENT
|
English | 38.0 KB | ||
| 2020-02-26 15:59 |
Reports Positive Results in the Final Cohort of its Phase 2b
Oral Insulin Trial
|
English | 207.0 KB | ||
| 2020-02-26 15:59 |
Reports Positive Results in the Final Cohort of its Phase 2b
Oral Insulin Trial
|
English | 37.9 KB | ||
| 2020-02-26 15:59 |
Form 8-K:Reports Positive Results in the Final Cohort of its Phase 2b Oral Insu…
|
English | 179.5 KB | ||
| 2020-02-26 15:59 |
Form 8-K:Reports Positive Results in the Final Cohort of its Phase 2b Oral Insu…
|
English | 37.9 KB | ||
| 2020-02-11 10:40 |
PROSPECTUS SUPPLEMENT (to prospectus dated February 10, 2020)
|
English | 197.8 KB | ||
| 2020-02-11 10:40 |
PROSPECTUS SUPPLEMENT (to prospectus dated February 10, 2020)
|
English | 37.9 KB | ||
| 2020-02-02 10:04 |
FORM S-3-REGISTRATION STATEMENT
|
English | 293.2 KB | ||
| 2020-02-02 10:04 |
FORM S-3-REGISTRATION STATEMENT
|
English | 37.9 KB | ||
| 2020-01-30 15:40 |
Oramed Appoints Dr. Julio Rosenstock to its Scientific Advisory Board
|
English | 189.9 KB | ||
| 2020-01-30 15:40 |
Oramed Appoints Dr. Julio Rosenstock to its Scientific Advisory Board
|
English | 37.9 KB | ||
| 2020-01-28 15:45 |
Oramed Patent in Europe to be Granted for Oral Delivery of Proteins
|
English | 206.2 KB | ||
| 2020-01-28 15:45 |
Oramed Patent in Europe to be Granted for Oral Delivery of Proteins
|
English | 37.9 KB | ||
| 2020-01-21 15:49 |
Oramed Appoints Dr. Jay Skyler to Scientific Advisory Board
|
English | 163.1 KB |
Automate Your Workflow. Get a real-time feed of all Oramed Pharmaceuticals Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Oramed Pharmaceuticals Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Oramed Pharmaceuticals Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
